Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Gemcitabine

Gemcitabine ▴ Gemcitabine has well established antitumor activity against a variety of solid tumors, including ovarian cancer, and hematologic malignancies. It has recently been approved in several European countries for use with carboplatin for the treatment of advanced ovarian cancer in patients with recurrent disease ≥6 months after platinum-based, first-line therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Loading next page...
 
/lp/springer-journals/gemcitabine-7N2X6MHud0
Publisher
Springer Journals
Copyright
Copyright © 2005 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200504050-00011
Publisher site
See Article on Publisher Site

Abstract

▴ Gemcitabine has well established antitumor activity against a variety of solid tumors, including ovarian cancer, and hematologic malignancies. It has recently been approved in several European countries for use with carboplatin for the treatment of advanced ovarian cancer in patients with recurrent disease ≥6 months after platinum-based, first-line therapy.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References